OncoTargets and Therapy
Volume 10, 2017 - Issue
Open access
55
Views
8
CrossRef citations to date
0
Altmetric
Review
Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
Hampig Raphael Kourie1 Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
, Elie El Rassy1 Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
, Florian Clatot2 Department of Medical Oncology and IRON/U1245, Centre Henri Becquerel, Rouen, France;3 Breast Cancer Translational Research Laboratory
, Evandro de Azambuja4 Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
& Matteo Lambertini3 Breast Cancer Translational Research Laboratory;4 Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BelgiumCorrespondence[email protected]
Pages 3363-3372
|
Published online: 10 Jul 2017
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.